Publications by authors named "Marcos Timon"

Claim this Profile
H
Hospital Exemption for Advanced Therapy Medicinal Products in Spain.
Marcos Timón, Sol Ruiz

Hum Gene Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective.
Laura Rodríguez, Pablo de Felipe, Raquel Martín, Jorge Martínez, David Ordóñez

Hum Gene Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMA commentary on the guideline on quality, nonclinical and clinical aspects of medicinal products containing genetically modified cells.
Patrick Celis, Giada Farinelli, Ana Hidalgo-Simon, Pauline Meij, Mara Tihaya

Br J Clin Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Martina Schuessler-Lenz, Carla Herberts, Ilona Reischl, Sol Ruiz, Patrick Celis

Adv Exp Med Biol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
Juan Estévez Álamo, Marcos Timón, Isabel Sánchez Afán de Rivera, Beatriz Iriarte Torres, M Antonia Serrano Castro

Adv Exp Med Biol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enough.
Ursula Loizides, Massimo Dominici, Tony Manderson, Menico Rizzi, James S Robertson

Cytotherapy· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use.
Paula Salmikangas, Margarida Menezes-Ferreira, Ilona Reischl, Asterios Tsiftsoglou, Jan Kyselovic, Marcos Timon

Regen Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges with advanced therapy medicinal products and how to meet them.

Nat Rev Drug Discov· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leishmania infection: laboratory diagnosing in the absence of a "gold standard".
Alhelí Rodríguez-Cortés, Ana Ojeda, Olga Francino, Laura López-Fuertes, Marcos Timón

Am J Trop Med Hyg· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Alhelí Rodríguez-Cortés, Ana Ojeda, Laura López-Fuertes, Marcos Timón, Laura Altet

Vaccine· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A long term experimental study of canine visceral leishmaniasis.
Alhelí Rodríguez-Cortés, Ana Ojeda, Laura López-Fuertes, Marcos Timón, Laura Altet

Int J Parasitol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis